ClinicalTrials.gg
RecruitingNCT02686229LoG-GlioUpdated May 11, 2023

Registry Study on Epidemiological and Biological Disease Profile as Well as Clinical Outcome in Patients With Low Grade Gliomas

An observational study in Glioma, sponsored by University of Ulm. Recruiting at 1 site in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-05-11.

Sponsored by University of Ulm · Observational

How we know

From the registry’s dates

  • Started Nov 2015; still recruiting 11 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
300
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 70 studies in Glioma with a site in Germany — 20 open to participants now, 29 under way, 3 of them phase 3. Glioma · Germany.

Planned enrollment
4th of 11
300 · median 150
Started
2015
with 4 others
Observational
11 of 70
6 open now
Primary completion
2026-12
later than 8 of 28 live
Registered
28th of 70
by date

Among the 70 studies in Glioma with a site in Germany, this one is the 4th largest by planned enrollment of the 11 observational ones that give a count, is one of 5 that started in 2015, is one of 11 observational ones, reaches primary completion later than 8 of the 28 other live ones, and was the 28th registered.

Glioma

1,456 studies on the registry are indexed under Glioma; 351 are open to participants now.

Browse Glioma studies →

Open to participants now

20 of the 70 studies in Glioma with a site in Germany are open now. Recruiting first, the newest first:

14 more — sign in →

All 20 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 267 Glioma studies recruiting now, 165 (62%) set no upper age limit and 57 (21%) stop at 75 or younger; 63 take children under 18; 15 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 70 studies in Glioma with a site in Germany, or all of them as a file.
02

Study summary

The LoG-Glio-Registry is based on a network of german hospitals gathering radiological, clinical, epidemiological and molecular data on all patients diagnosed with a low grade glioma.

03

Conditions studied

  • Glioma

Keywords

  • Low grade glioma, registry, neurosurgery, brain tumor
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

All adult patients with radiological suspected diagnosis of a low grade glioma

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with radiological suspected diagnosis of a low grade glioma
  • Age ≥ 18 years. There is no upper age limit.

Exclusion criteria

Exclusion Criteria:

  • Severe neurological or psychiatric disorder interfering with ability to give an
  • No consent for registration, storage and processing of the individual disease characteristics and course as well as information of the family physician about study participation
  • No consent for bio-banking of patient's biological specimens and performance of analyses on stored material.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
300 participants (estimated)
Target follow-up
10 Years
Patient registry
Yes
Biospecimen retention
Samples with dna

Interventions

  • Otherno interventions
06

What researchers measure

Primary outcomes

  1. Progression-free survival (PFS)

    Time frame: 5yrs

  2. Overall survival (OS)

    Time frame: 15yrs

Secondary outcomes

  1. Extent of tumor resection

    calculated based on volumetric assessement of tumor in cm³ and residual tumor in pre and postoperative MRI

    Time frame: 3yrs

  2. Quality of life (QoL) assessed by the EORTC QLQ C-30/BN-20. (European Organisation for Research and Treatment of Cancer Quality of Life Questionaire C-30

    Time frame: 5yrs

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Pala A, Nadji-Ohl M, Faust K, Ruckriegel S, Roder C, von der Brelie C, Forster MT, Lobel F, Schommer S, Lohr M, Renovanz M, Grubel N, Rothenbacher D, Konig R, Engelke J, Schmitz B, Wirtz CR, Ringel F, Senft C, Rohde V, Tatagiba M, Ernestus RI, Vajkoczy P, Ganslandt O, Nagel G, Coburger J. Multicentric Registry Study on Epidemiological and Biological Disease Profile as Well as Clinical Outcome in Patients with Low-Grade Gliomas: The LoG-Glio Project. J Neurol Surg A Cent Eur Neurosurg. 2020 Jan;81(1):48-57. doi: 10.1055/s-0039-1693650. Epub 2019 Sep 24. Erratum In: J Neurol Surg A Cent Eur Neurosurg. 2020 Jan;81(1):e1. doi: 10.1055/s-0040-1712923. PubMed 31550737 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2015 (actual). Primary completion is estimated for Dec 2026, 133 months after the start.

Of 115 non-industry observational studies under Glioma, half reached primary completion within 67 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 104. This study's planned 133 months is above that.

Counting every sponsor, half of 125 studies reached it within 60 months; a quarter within 29 and three quarters within 104.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 4, 2016
First posted
Feb 19, 2016
StartActual
Nov 15, 2015
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 2036
Last update
May 11, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 11, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02686229
Lead sponsor
University of Ulm
Responsible party
Jan Coburger (M.D., University of Ulm) — Principal investigator
First posted
Feb 19, 2016
Start date
Nov 15, 2015
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 2036 (estimated)
Last update
May 11, 2023

Study contacts

Jan Coburge, MD
Contact
jan.coburger@uni-ulm.de
082219628858

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion